A Single-arm, Open, Clinical Study to Evaluate the Effects of Fimasartan on Arterial Stiffness in Patients With Hypertension
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms STIFFNESS
- Sponsors Boryung Pharmaceutical
- 21 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.
- 21 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.